Introduction
Murine double minute 2 (mdm2) is an oncogene whose protein product functions as a major negative regulator of the tumor suppressor, p53. p53 inhibits cell growth by causing both cell-cycle arrest and apoptotic pathways in damaged cells (Levine, 1997) . Through direct association with p53, Mdm2 blocks p53 transactivation and targets p53 for degradation via the ubiquitinproteosome pathway (Haupt et al., 1997; Kubbutat et al., 1997) . Although, degradation of p53 is triggered by Mdm2-dependent ubiquitination, direct binding of Mdm2 with p300 appears to be necessary to complete the proteosome-mediated degradation process (Grossman et al., 1998; Zhu et al., 2001) . Thus, Mdm2 is a nuclear protein that is capable of interacting with proteins involved in regulating transcription, the cell cycle and apoptosis.
MdmX was initially discovered as a protein capable of interacting with p53 that possessed significant homology to Mdm2 (Shvarts et al., 1996) . Like Mdm2, MdmX is expressed in all human and murine tissues; however unlike Mdm2, MdmX is not regulated by p53 (Jackson and Berberich, 1999; Shvarts et al., 1996) . Recently, mice lacking mdmX were shown to result in embryonic lethality that could be rescued by eliminating p53 (Finch et al., 2002; Migliorini et al., 2002; Parant et al., 2001 ), a result which parallels a previous report for Mdm2 . Although MdmX binds p53 and inhibits p53 transactivation it cannot degrade p53 (Jackson and Berberich, 2000) but is capable of associating with Mdm2 (Tanimura et al., 1999) .
While the biological activities of Mdm2 and MdmX seem to suggest the primary role for these proteins is to regulate p53 and perhaps each other, evidence has begun to accumulate suggesting Mdm2 and MdmX may affect other cellular activities (Lundgren et al., 1997) or proteins (Jackson et al., 2001) . Of particular interest was the finding that Mdm2 overexpression could inhibit the transforming growth factor-beta (TGF-b) signaling pathway (Sun et al., 1998) . TGF-b is a multifunctional cytokine and a tumor suppressor (Piek et al., 1999) that is inactivated in many human tumors (Thomas and White, 1998) . TGF-b is a strong activator of genes such as fibronectin and plasminogen activator inhibitor (PAI) (Datta et al., 2000; Penttinen et al., 1988; Sandler et al., 1994; Teruel et al., 1995) and a potent inhibitor of cell growth in numerous cell types (Massague, 1998; Massague et al., 2000) . Additionally, TGF-b functions as an important inhibitor of genes that promote cell cycle progression into S phase, such as c-Myc, cdc25A, and G1 cyclindependent kinases (Brown et al., 1998; Ivarone and Massague, 1999; Warner et al., 1992) . TGF-b signaling is predominantly transduced through the activation of the Smad family of proteins (Massague, 1998) . The Smads are a family of intracellular proteins that positively and negatively regulate signaling by TGF-b. Smad proteins transduce signals from activated TGF-b receptor complexes via phosphorylation of serine/threonine residues present at the C-terminus of regulatory Smads (Smad 2,3; R-Smads). Phosphorylation of R-Smads initiates binding with Co-Smad4 promoting heteroligomerization, nuclear translocation, and transcriptional activation (Datto and Wang, 2000; Derynck et al., 1998; Massague et al., 2000; Wrana, 2000; Wrana and Attisano, 2000) .
A major regulator of Smad transactivation is the transcription factor p300 Feng et al., 1998; Pouponnot et al., 1998; Shen et al., 1998) . p300 is a nuclear co-activator for numerous transcriptional complexes and belongs to a unique class of co-activators possessing histone acetyltransferase activity (Giordano and Avantaggiati, 1999) . p300 forms a ternary complex with phosphorylated R-Smad/CoSmad4 complex and allows Smads to access and bind DNA. Interference with nuclear co-activators like p300 or the presence of repressor proteins has been shown to inhibit Smad transactivation (Akiyoshi et al., 1999; Datto and Wang, 2000; Derynck et al., 1998; Kim et al., 2000; Wrana, 2000; Wrana and Attisano, 2000) .
Following an initial report showing that constitutive mdm2 overexpression could lead to TGF-b resistant colony formation, independent of p53 (Sun et al., 1998) , two other groups explored the molecular basis of Mdm2 dependent TGF-b resistance Yam et al., 1999) . Yam et al. (1999) reported that Mdm2 and MdmX overexpression could inhibit the transcriptional activity of Smads, potentially through nuclear exclusion. Another group, attempting to reproduce the original findings of Mdm2-dependent TGF-b resistance, used mdm2 inducible cell lines but were unable to demonstrate that transient mdm2 overexpression could affect TGF-b growth inhibition .
In this study we examined the role of MdmX and Mdm2 in regulating the reporter activity of TGF-b responsive promoters. Here we demonstrate that MdmX but not Mdm2 is an effective inhibitor of Smad transactivation, independent of p53. MdmX inhibition of Smad transactivation does not require the p53 or Mdm2 interaction domains and MdmX overexpression could block Smad transactivation in a TGF-b sensitive cell line. Unlike previous reports, MdmX inhibition of Smad transactivation did not result from an alteration of Smad nuclear accumulation. However, the inhibition of Smad transactivation by MdmX could be reversed by overexpression of p300. Based on these results, we propose that MdmX represents a novel regulator of TGF-b signaling through its effects on Smad/p300 association. (Figure 1a ,b, lane 2) caused a significant increase in transactivation compared to reporter alone (lane 1). We observed no significant effect on Smad3 or Smad4 transactivation in presence of increasing concentrations of Mdm2 (Figure 1a ,b, lanes 3 and 4). In contrast, co-transfection of MdmX led to a significant decrease in both Smad3 and Smad4 transactivation compared to reporter alone (Figure 1a ,b, lanes 5 and 6). Additionally, neither Mdm2 nor MdmX significantly affected Smad3 or Smad4 protein levels ( Figure 1a ,b, lower panels). Thus our results with MdmX but not Mdm2 were consistent with those previously reported (Yam et al., 1999) namely that MdmX overexpression could alter Smad transactivation. Based on the inhibition seen with MdmX on Smad transactivation, we decided to examine the domains of MdmX protein that were required for this repressive activity.
Results

Mdm2 and MdmX effects on Smad induced transactivation
Effects of MdmX mutants on Smad induced transactivation
To define the regions within MdmX that were responsible for the inhibitory effect on Smad3 and Smad4 induced transactivation, various MdmX deletion mutants were tested (Jackson and Berberich, 2000) . Increasing concentrations of MdmX Dp53, MdmX DRF and MdmX Dp53DRF each resulted in a dose dependent decrease in both Smad3 (Figure 2a ) and Smad4 (Figure 2b ) transactivation but caused no dramatic change in Smad protein levels (Figures 2a,b , second panels). The inhibition of Smad transactivation by an MdmX protein lacking both the p53 and Mdm2 binding domains strongly argues that MdmX inhibition of Smad transactivation is independent of both p53 and Mdm2. Consistent with that model, overexpression of either MdmX CtCC (Figure 2a ,b, lanes 9 -10) or MdmX (1 -127), which retains the p53 binding region (amino acids 1 -127, data not shown), exhibited no dramatic effect on either Smad3 or Smad4 transactivation. MdmXDp53DRF represents the smallest region of MdmX that elicited inhibition of Smad transactivation suggesting that the region required to cause inhibition of Smad transactivation is encoded by amino acid residues 128 -444 of MdmX. Based on sequence homology with Mdm2, this region of MdmX aligns most closely with the p300 binding region of Mdm2 (Grossman et al., 1998) .
Smad transactivation and retain the region of MdmX that aligns with the p300 binding region of Mdm2, we next examined whether MdmX inhibition of Smad transactivation could be blocked by overexpression of p300. Various groups have shown that Smad induced transactivation requires p300 binding and is significantly augmented by the co-activator p300 Feng et al., 1998; Pouponnot et al., 1998; Shen et al., 1998) . H1299 cells were transfected with the plasmid encoding p3TP-lux either alone or with the indicated combinations of Smad3, Smad4, MdmX and p300 plasmids (Figure 3a ,b). As previously reported , the cotransfection of p300 with either Smad3 or Smad4 further augmented Smad transactivation (Figure 3a ,b, lanes 3). Increasing concentrations of MdmX in the presence of a constant level of p300 and Smad3 ( Figure  3a ) led to modest decrease in Smad3 and p300 induced transactivation while increasing concentrations of MdmX in presence of Smad4 and p300 completely eliminated the p300 effect ( Figure 3b ). To confirm this, the effects of MdmX deletion mutants on Smad3/p300 or Smad4/p300 induced transactivation were also examined. In Figure 4 , H1299 cells were transfected with reporter plasmid p3TP-lux alone or with the indicated combinations of either Smad3, Smad4, p300 and MdmX deletion mutants, MdmXDp53, MdmXDRF, MdmXDp53DRF or MdmXCtCC. A dose dependent decrease in Smad plus p300 transactivation is observed in cells transfected with MdmXDp53, MdmXDRF, and MdmXDp53DRF but not MdmXCtCC. As with full-length MdmX ( Figure  3 ), the effects of the MdmX deletion mutants were more pronounced with Smad4/p300 than Smad3/p300 ( Figure 4 ). Taken together, these results are consistent with a model that MdmX inhibition of Smad transactivation occurs through competition between p300 and MdmX. 
Nuclear localization of Smad3 or Smad4 is not affected by co-expression of Mdm2 or MdmX
A previous study (Yam et al., 1999) suggested that Mdm2 and MdmX inhibition of Smad transactivation resulted from the nuclear exclusion of Smads. Although we observed no effect of Mdm2 overexpression on Smad transactivation to test this model, immunofluorescence studies were performed to determine if either Mdm2 or MdmX overexpression led to an altered cellular localization of Smads. H1299 cells were transfected with either Smad3 (Figure 7a MdmX induced inhibition of Smad transactivation is not due to cytoplasmic sequestration of Smads but rather is consistent with a model suggesting that MdmX may affect Smad transactivation by exerting its effect through p300.
MdmX associates with Smad3, Smad4 and p300
Lastly, to test whether the effect of MdmX on Smad transactivation is through direct competition with p300 for binding to Smads or a quenching of Smad transactivation by binding up of p300, MdmX binding to p300 and Smad3 or Smad4 were determined in vitro. The 35 S labeled N-terminal p300 (1 -595) and Cterminal p300 (619 -2414) fragments, Smad3 and Smad4 and Mdm2 (positive control) were individually incubated with recombinant MdmX. The reactions were subsequently immunoprecipitated with a polyclonal anti-MdmX antibody and immunoprecipitates resolved using SDS -PAGE. As shown in Figure 8a , both the N and C-terminal regions of p300 coimmunoprecipitated with MdmX, suggesting that MdmX is capable of binding to p300 at multiple sites. Similarly, Smad3, Smad4 and Mdm2 (Figure 8b ,c) also co-immunoprecipitated with MdmX. These results were (Figure 8b ,c) or immunoprecipitated with recombinant RPA using an RPA antibody (data not shown) showed no detectable radiolabeled Smad or Mdm2 proteins. Taken together, these co-immunoprecipitation results imply that MdmX could inhibit Smad transactivation by either association with Smads or p300. We are presently determining the MdmX binding domains for p300 and Smad to determine if one or both of them colocalize with the MdmX domain (amino acids 128 -444) responsible for inhibiting Smad transactivation.
Discussion
The goal of this study was to determine whether Mdm2 or MdmX overexpression mediated regulation of Smad transactivation. Smad proteins are the downstream elements of the TGF-b signaling pathway. In this report we demonstrated that MdmX, but not Mdm2 inhibits Smad3 and Smad4 transactivation when these Smads are individually overexpressed. While the inhibition of Smad transactivation by MdmX was previously reported, the inability of Mdm2 to block Smad transactivation seems to contrast the results seen by Yam et al. (1999) . It should be noted that we could not directly compare our results with those by Yam et al. (1999) since no information was available regarding the ratio or amounts of Smad : Mdm2 expression plasmids used.
Based on screening a series of MdmX deletion mutants, the region of MdmX involved in inhibition of Smad transactivation was localized to amino acids 128 -444. It therefore seems unlikely that MdmX association with either p53 or Mdm2 plays any vator, p300. Initially we tested whether the inability of Mdm2 to elicit a similar effect might result from the differences in protein stability between Mdm2 and MdmX (Levine, 1997) . Using a Mdm2 protein lacking the Ring Finger domain that contains E3 ligase activity or treating Mdm2 transfected cells with MG132, a proteosome inhibitor, both failed to allow Mdm2 to inhibit Smad transactivation at a level equivalent to MdmX (data not shown). It has already been shown that binding of p300 to Smads is essential for Smad transactivation . Therefore while p300 may be the limiting factor in Smad transactivation and the binding of MdmX to p300 negatively affects Smad transactivation, the inability of Mdm2 to elicit a similar effect may suggest that other interactions within the MdmX domain 128 -444, not present in Mdm2, may also play an important role in regulating Smad transactivation. Nevertheless, p300 is a critical element in this regulation as demonstrated in Figures 3 and 4 where the dose-dependent inhibition of Smad transactivation by MdmX and MdmX deletion mutant was less dramatic in presence of constant amounts of exogenous p300.
Inhibition of Smad transactivation by MdmX and MdmX deletion mutants as shown in Figures 1 and 2 further suggests that p300 binds to MdmX. In vitro binding of MdmX to p300 (Figure 7) demonstrates that MdmX bound to both the C-terminal as well Nterminal region of p300 suggesting that MdmX binds to p300 at multiple sites.
The possibility that Mdm2 and MdmX repressed Smad transactivation through nuclear exclusion was recently put forward (Yam et al., 1999) . While the ability of Mdm2 to undergo nucleocytoplasmic shuttling offers a plausible mechanism to explain how Mdm2 might alter the localization of associated proteins, our results (Figure 1 ) indicate Mdm2 showed no significant inhibition of Smad transactivation. However, MdmX which was an effective inhibitor for Smad 3 and Smad 4 transactivation (Figure 1) does not undergo nucleocytoplasmic shuttling as reported earlier (Jackson and Berberich, 2000) . The data in Figure 7 clearly demonstrates that neither Mdm2 nor MdmX overexpression resulted in any significant relocalization of Smad3 or Smad4. The in vitro binding of MdmX to Smad3 and Smad4 by immunoprecipitation (Figure 8 ) suggests that MdmX may alternatively inhibit Smad transactivation via direct association with Smads. Whether MdmX overexpression leads to association with Smads prohibiting p300 binding or through association with p300 leading to a loss of Smad : p300 complexes is currently under investigation. Our data demonstrate that MdmX represses Smad transactivation independent of p53 or Mdm2. These findings provide new insights into the regulation of Smad transactivation and will allow for further studies to decipher the role of MdmX in causing resistance to TGF-b and the potential loss of tumor suppressor activity. 
Materials and methods
Plasmids
Expression plasmids encoding mdm2, mdmX and various mdmX deletions were constructed as previously described (Jackson and Berberich, 2000) . mdmx CtCC represents a deletion mutant lacking the first 364 amino acid residues cloned into pFLAG-CMV2. MdmX Dp53 (aa 128 -489) lacks the p53 binding domain of p53, MdmX DRF (aa 1 -444) lacks the Mdm2 binding domain and MdmX Dp53DRF (aa 128 -444) lacks both the p53 and Mdm2 binding domains (Jackson and Berberich, 2000) . p3TP-lux was used for Smad Representative examples of Smad3 (a) and Smad4 (b) staining demonstrating both nuclear and cytoplasmic localizations of both Smad3 and Samd4 in the presence or absence of Mdm2 or MdmX transactivation studies and contains three repeats of a plasminogen activator inhibitor type 1 (PAI-1) sequence responsive to TGF-b (Massague, 1998; Massague et al., 2000) . The pQE-bgal expression plasmid was used to normalize for transfection efficiency. pRK5-Smad3 and pRK5-Smad4 were provided from R Derynck, (UCSF). The plasmid encoding the full length p300 (CMVp300) was obtained from Shelly Barton, MD Anderson Cancer Center. pBp300 (1 -595) and pBp300 (619 -2414) expression plasmids encoding the N-terminal or C-terminal region of p300 were a gift from S Grossmann, Dana-Farber Cancer Institute (Grossman et al., 1998) .
Cell lines and transfection
H1299 cells are a non-small-lung carcinoma cell line devoid of p53. HepG2, a TGF-b sensitive cell line, was obtained from the American Type Culture Collection. 1KO, 2KO and X KO devoid of either p53 alone, p53 and Mdm2 or p53 and MdmX, respectively were obtained from Gigi Lozano. All cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum and 10 mg/ml gentamicin. H1299 cells (5.5610 5 cells/60 mm plates) were transiently transfected in serum-and antibioticfree DMEM with the indicated amount of plasmids using Lipofectamine (GIBCO, BRL). After a 5 h incubation, the medium was replaced with DMEM containing 10% fetal bovine serum and 10 mg/ml gentamicin. At 24 h post transfection, cells were harvested and whole cell lysates were prepared as previously described (Jackson and Berberich, 2000) .
Immunoblotting studies
Protein extracts based on equivalent calculated b-galactosidase activities were fractionated by SDS -PAGE and transferred to a PVDF membrane. The membranes were subsequently subjected to immunoblotting using either antiSmad3 polyclonal antibody (Zymed), anti-Smad4 monoclonal antibody (Santa Cruz Biotechnology), anti-Mdm2 (2A10) monoclonal antibody or anti-MdmX polyclonal antibody (Jackson and Berberich, 1999) . Appropriate horseradish peroxidase-conjugated secondary antibodies were used for chemiluminescence detection.
Transactivation assays
With the exception of Figure 5 , whole cell lysates were prepared 24 h following transfection and assayed for luciferase and b-galactosidase activity as previously described (Kadakia et al., 2001) . Transactivation activity was plotted as relative luciferase units (luciferase activity/milliunits of b-gal activity).
In-vitro transcription and translation 35 S-Methionine labeled in vitro translated proteins from pBp300(1 -595), pBp300 (619 -2414), pRK5Smad3, pRK5Smad4 and Mdm2 expression plasmids were synthesized using a coupled transcription and translation TnT kit (Promega).
Immunoprecipitation
Immunoprecipitation studies were performed by incubating the 35 S radiolabeled p300, Smad3, Smad4 or Mdm2 TnT translated products with recombinant MdmX protein overnight at 48C in a Binding Buffer (Phosphate buffered saline (PBS) pH 7.4 containing 5 mM EDTA and 0.5% Triton X-100) containing 4 ml of polyclonal MdmX antibody. Next day, 25 ml of Protein G Agarose was added to each reaction and the samples were incubated at 48C with rocking for two additional hours. The tubes were spun in a microfuge for 1 min, and the supernatant was discarded. The pellet was then washed four times for 5 min each in the Binding Buffer. Following the final wash, the immunoprecipitates were resuspended in 25 ml of 26 SDS loading buffer and boiled for 5 min. The immunoprecipitated proteins were resolved using 7.5% SDS -PAGE. Following electrophoresis, the gel was fixed in 40% methanol and 10% acetone, followed by treatment with 1 M salicyclic acid. The gel was dried under vacuum and subjected to autoradiography for 1 -2 days.
Colocalization studies using immunofluorescence H1299 cells were transfected with Flag-tagged versions of Smad3 or Smad4 expression plasmids in presence of fivefold excess of either Mdm2-EGFP or MdmX-EGFP expression plasmids. At 5 h post-transfection, cells were trypsinized, counted and 2610 4 cells (per well) replated onto 164 LabTek chamber slides. Immunofluorescence analysis was performed 24 h following transfection. Cells were fixed in 3% paraformaldehyde and permeabilized with PBS containing 1% Triton X-100. The fixed cells were incubated overnight at 48C in Blocking Buffer (PBS containing 10% goat serum and 0.2% Tween 20). The cells were then treated with primary antibody (anti-Flag M1; Sigma) diluted to 7.5 mg/ml using 0.16 Blocking Buffer for 2 h. The slides were washed five times for 10 min each with the diluted Blocking Buffer and subsequently incubated for 1 h with goat antimouse Texas Red conjugated antibody (1.5 mg/ml). Lastly, the slides were washed and incubated with 25 mg/ml Hoechst Dye for 5 min at room temperature followed by two more 5 min washes in diluted Blocking Buffer prior to the addition of permamount and coverslip.
